KR900002791A - 면역억제를 위한 플라스미노겐 활성인자 억제 인자(pai-2)의 용도 - Google Patents

면역억제를 위한 플라스미노겐 활성인자 억제 인자(pai-2)의 용도 Download PDF

Info

Publication number
KR900002791A
KR900002791A KR1019890012458A KR890012458A KR900002791A KR 900002791 A KR900002791 A KR 900002791A KR 1019890012458 A KR1019890012458 A KR 1019890012458A KR 890012458 A KR890012458 A KR 890012458A KR 900002791 A KR900002791 A KR 900002791A
Authority
KR
South Korea
Prior art keywords
formulation
prepared
use according
treatment
prevention
Prior art date
Application number
KR1019890012458A
Other languages
English (en)
Inventor
스티이프 토마스
하임부르거 노베르트
울리히 숄렘머 한스
Original Assignee
필립 스타인, 헤리베르트 북
베링베르케 아크티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 필립 스타인, 헤리베르트 북, 베링베르케 아크티엔게젤샤프트 filed Critical 필립 스타인, 헤리베르트 북
Publication of KR900002791A publication Critical patent/KR900002791A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

내용 없음

Description

면역억제를 위한 플라스미노겐 활성인자 억제 인자(PAI-2)의 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (13)

  1. 면역 억제제 활성을 지닌 제제의 제조 공정에 사용하기 위한 플라스미노겐 활성 인자 억제 인자(PAI-2)의 용도.
  2. 제 1 항에 있어서, 제제가 플라스미노겐 활성 인자 억제 인자-2의 용량(체중 75kg)당 52 내지 2.25×106유로키나제-억제 단위를 함유하는 용도.
  3. 제 1 항에 있어서, 제제가 안정화제, 바람직하게는 알부민 또는 분해되고 가교결합된 젤라틴 또는 분해되고 가교결합된 콜라겐을 함유하는 용도.
  4. 제 1 항에 있어서, 제제가 이식 조직- 및 태반-거부 발증 및 이식 조직-숙주 반응의 치료 및 예방을 위해 제조되는 용도.
  5. 제 1 항에 있어서, 제제가 자가 면역 질환의 치료를 위해 제조되는 용도.
  6. 제 1 항에 있어서, 제제가 상처 및 골 치유 장해의 치료 및 예방을 위해 제조되는 용도.
  7. 제 1 항에 있어서, 제제가 산소 라디칼의 증가된 형성과 연관된 병리학적 과정의 치료를 위해 제조되는 용도.
  8. 제 1 항에 있어서, 제제가 급성 재관류 중 및 후에 발생하는 조직 손상의 치료 및 예방을 위해 제조되는 용도.
  9. 제 1 항에 있어서, 제제가 지망막하 출혈의 출혈 후 합병증의 예방 및 치료를 위해 제조되는 용도.
  10. 제 1 항에 있어서 제제가 바람직하게는 피브린 접착제, 상처-치유 분무제 또는 천식 치료 분무제 또는 화상 치유 분무제로서 국부 투여를 위해 제조되거나 증가된 백혈구 활성과 연관된 기능 장애의 치료 및 예방을 위해 제조되는 제제의 용도.
  11. 제 1 항에 있어서, 제제가 단핵구/대식구 시스템을 억제시키기 위해 제조되는 용도.
  12. 플라스미노겐 활성 인자 억제 인자 및 오르니틴 데카복실레이트 억제 인자, 바람직하게는 트랜스 글루타미나제, 특히 바람직하게는 인자 XⅢ를 함유하는 약제.
  13. 제12항에 있어서, 2.25×106단위 이하의 PAI-2 및 52 내지 225,000단위의 트랜스글루타미나제를 함유하는 약제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890012458A 1988-08-31 1989-08-31 면역억제를 위한 플라스미노겐 활성인자 억제 인자(pai-2)의 용도 KR900002791A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP3829523.7 1988-08-31
DE3829523A DE3829523A1 (de) 1988-08-31 1988-08-31 Verwendung von plasminogen-aktivator-inhibitor (pai-2) zur immunsuppression

Publications (1)

Publication Number Publication Date
KR900002791A true KR900002791A (ko) 1990-03-23

Family

ID=6361973

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890012458A KR900002791A (ko) 1988-08-31 1989-08-31 면역억제를 위한 플라스미노겐 활성인자 억제 인자(pai-2)의 용도

Country Status (9)

Country Link
EP (1) EP0356945B1 (ko)
JP (1) JPH02108633A (ko)
KR (1) KR900002791A (ko)
AT (1) ATE97576T1 (ko)
AU (1) AU616555B2 (ko)
DE (2) DE3829523A1 (ko)
DK (1) DK428089A (ko)
ES (1) ES2061842T3 (ko)
PT (1) PT91584B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100550385B1 (ko) * 2002-11-11 2006-02-08 메타볼랩(주) 트랜스글루타미나아제를 포함하는 칸디다 속의 미생물과그의 숙주 세포 사이의 결합 저해제

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4214215A1 (de) * 1992-04-30 1993-11-04 Behringwerke Ag Verwendung von inhibitoren von plasminogenaktivatoren zur behandlung von entzuendungen
KR20010042402A (ko) * 1998-04-01 2001-05-25 로잘란드 앤 칼도르 피부 상처의 치료를 위한 프로테아제 억제제의 용도
AUPP508798A0 (en) * 1998-08-05 1998-08-27 Biotech Australia Pty Limited Method of treating psoriasis
EP1066834A3 (de) * 1999-07-08 2004-06-02 Thomas Dr. Stief Pharmazeutische Zusammensetzungen enthaltend ein phagozytenmodulierendes Agens
ES2243314T3 (es) 1999-10-27 2005-12-01 Alexandra Lucas Composiciones para la prevencion y el tratamiento del rechazo de trasplantes.
AUPQ380699A0 (en) * 1999-11-02 1999-11-25 Biotech Australia Pty Limited Protease inhibitors as modulators of periodontal wound healing
US7419670B2 (en) 2000-09-29 2008-09-02 Viron Therapeutics, Inc. Method of treating arthritis with SERP-1 and an immunosuppressant
JP4578067B2 (ja) * 2003-06-06 2010-11-10 宏 清水 局所医薬組成物
US7285530B2 (en) 2004-10-21 2007-10-23 Viron Therapeutics, Inc. Use of SERP-1 as an antiplatelet agent

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923807A (en) * 1984-05-18 1990-05-08 New England Medical Center Hospitals Inc. Arg-Serpin human plasminogen activator inhibitor designated PAI-2
US4851345A (en) * 1985-01-14 1989-07-25 Terumo Kabushiki Kaisha Fibrinophilic urokinase complex and method for production thereof
DE3713272A1 (de) * 1987-04-18 1988-11-03 Behringwerke Ag Plasminogenaktivator-inhibitor, typ 2 (pai-2)
DE3829524A1 (de) * 1988-08-31 1990-03-01 Behringwerke Ag Verwendung von transglutaminasen als immunsuppressiva

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100550385B1 (ko) * 2002-11-11 2006-02-08 메타볼랩(주) 트랜스글루타미나아제를 포함하는 칸디다 속의 미생물과그의 숙주 세포 사이의 결합 저해제

Also Published As

Publication number Publication date
JPH02108633A (ja) 1990-04-20
ATE97576T1 (de) 1993-12-15
EP0356945A3 (de) 1991-07-31
DK428089D0 (da) 1989-08-30
DK428089A (da) 1990-03-01
EP0356945A2 (de) 1990-03-07
AU4090589A (en) 1990-03-08
ES2061842T3 (es) 1994-12-16
DE3829523A1 (de) 1990-03-01
AU616555B2 (en) 1991-10-31
PT91584B (pt) 1995-05-31
DE58906241D1 (de) 1994-01-05
PT91584A (pt) 1990-03-08
EP0356945B1 (de) 1993-11-24

Similar Documents

Publication Publication Date Title
Lindner et al. Comparison of standard and high‐dose adrenaline in the resuscitation of asystole and electromechanical dissociation
ID24901A (id) Metode pengobatan keadaan terkoagulasi tinggi atau defisiensi protein c yang diperoleh
ES2166783T3 (es) Factor viii activado utilizado como agente terapeutico y metodo para el tratamiento de la deficiencia de factor viii.
DE69722401D1 (de) Kombinationen von vasopressin und adrenergischen wirkstoffen zur behandlung des plötzlichen herztods
BG60253B1 (bg) Човешки тъканен плазминогенен активатор
KR900002791A (ko) 면역억제를 위한 플라스미노겐 활성인자 억제 인자(pai-2)의 용도
DE59607342D1 (de) Verwendung von Prolin als einziger therapeutischer Wirkstoff zur Herstellung eines Arzneimittels zur Behandlung von rheumatischen Erkrankungen und von chronischen und traumatisch bedingten Schmerzzuständen
DE68912195T2 (de) Verwendung von Pyrrolicloncarbonsäurealkylestern zur Herstellung eines Arzneimittels zur Behandlung von Ichtyosis.
KR900002802A (ko) 면역억제제로서의 트랜스글루타미나제의 용도
Botta et al. Cardiac arrhythmias in phenol face peeling: a suggested protocol for prevention
CA2045605A1 (en) Treatment of leukocyte dysfunction with gm-csf
SGAPICCHIO et al. Comparative effects of silver nitrate and sulfamylon acetate on epidermal regeneration
Cerchiari et al. Effects of combined superoxide dismutase and deferoxamine on recovery of brainstem auditory evoked potentials and EEG after asphyxial cardiac arrest in dogs
EP1539225B1 (en) Apparatus and methods for use in enzymatic escharotomy in burn induced compartment syndrome
RU2781402C2 (ru) Ниосомальный антимикробный гель для лечения диабетических язв, ран, ожогов, в том числе инфицированных антибиотико-резистентными микроорганизмами
Shumacker JR et al. Studies in Experimental Frostbite: VI. Effect of Rutin and Benadryl With Some Notes on Plaster Casts and the Role of Edema
CA2036592A1 (en) Therapeutic agent for diabetic gangrene
BAXTER The effect of penicillin and streptomycin applied locally on the take of skin grafts
Schrems et al. The effect of topically applied prostaglandin inhibitors on the laser-induced disruption of the blood aqueous barrier
SU628904A1 (ru) Способ обезболивани
KR890000104A (ko) 외과수술시 초과산화물 디스뮤타아제의 사용방법
RU2169004C1 (ru) Ранозаживляющая композиция
RU2070065C1 (ru) Способ внутривенного общего обезболивания при аутодермопластике у обожженных
Robson et al. The burn wound
RU93042331A (ru) Глазные капли

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application